Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2008 1
2009 4
2010 3
2011 3
2012 10
2013 27
2014 6
2015 11
2016 9
2017 14
2018 15
2019 18
2020 34
2021 41
2022 45
2023 38
2024 35
2025 35
2026 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. Roos I, et al. JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625. JAMA Neurol. 2023. PMID: 37307006 Free PMC article.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. Among authors: shaygannejad v. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group; Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T, Granziera C. Müller J, et al. Among authors: shaygannejad v. JAMA Neurol. 2025 Jun 1;82(6):614-625. doi: 10.1001/jamaneurol.2025.0495. JAMA Neurol. 2025. PMID: 40227706 Free PMC article.
Editorial: CNS autoimmune disorders and COVID-19.
Mirmosayyeb O, Badihian S, Shaygannejad V, Hartung HP. Mirmosayyeb O, et al. Among authors: shaygannejad v. Front Neurol. 2023 Apr 4;14:1183998. doi: 10.3389/fneur.2023.1183998. eCollection 2023. Front Neurol. 2023. PMID: 37082445 Free PMC article. No abstract available.
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.
Shipley J, Beadnall HN, Sanfilippo PG, Yeh WZ, Horakova D, Havrdova EK, Hradilek P, Kalincik T, Roos I, Prat A, Girard M, Rous Z, Pavelek Z, Gerlach OHH, Lechner-Scott J, Alroughani R, Ozakbas S, Peterka M, Buzzard K, Skibina OG, Maimone D, Foschi M, Surcinelli A, Karabudak R, Spitaleri DLA, Lugaresi A, Tomassini V, Gouider R, Mrabet S, Ferrando BR, Hodgkinson S, Štourac P, Guimarães J, John NA, Macdonell RAL, Meca-Lallana JE, Butzkueven H, van der Walt A, Jokubaitis VG; MSBase Investigator Group. Shipley J, et al. JAMA Netw Open. 2025 Sep 2;8(9):e2531581. doi: 10.1001/jamanetworkopen.2025.31581. JAMA Netw Open. 2025. PMID: 40952740 Free PMC article.
Emotional competencies in multiple sclerosis.
Sadeghi-Bahmani D, Motl RW, Sadeghi Bahmani L, Mirmosayyeb O, Shaygannejad V, Mokhtari F, Gross JJ. Sadeghi-Bahmani D, et al. Among authors: shaygannejad v. Mult Scler Relat Disord. 2023 Oct;78:104896. doi: 10.1016/j.msard.2023.104896. Epub 2023 Jul 17. Mult Scler Relat Disord. 2023. PMID: 37595370
Thalamic asymmetry in Multiple Sclerosis.
Ramezani N, Davanian F, Naghavi S, Riahi R, Zandieh G, Danesh-Mobarhan S, Ashtari F, Shaygannejad V, Sanayei M, Adibi I. Ramezani N, et al. Among authors: shaygannejad v. Mult Scler Relat Disord. 2023 Sep;77:104853. doi: 10.1016/j.msard.2023.104853. Epub 2023 Jun 23. Mult Scler Relat Disord. 2023. PMID: 37473593
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Kalincik T, et al. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. JAMA Neurol. 2023. PMID: 37437240 Free PMC article.
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.
Sahraian MA, Abolfazli R, Shaygannejad V, Ashtari F, Majdinasab N, Navardi S, Baghbanian SM, Sedighi B, Naser Moghadasi A, Nahayati MA, Ghalyanchi Langroodi H, Mohammadianinejad SE, Beladi Moghadam N, Ayromlou H, Nikseresht A, Ghiasian M, Razazian N, Asadollahzadeh E, Sabzvari A, Kafi H, Albooyeh S. Sahraian MA, et al. Among authors: shaygannejad v. Sci Rep. 2024 Oct 22;14(1):24921. doi: 10.1038/s41598-024-75745-y. Sci Rep. 2024. PMID: 39438591 Free PMC article. Clinical Trial.
332 results